Insider Selling: Quidel Corporation (QDEL) SVP Sells 16,358 Shares of Stock
Quidel Corporation (NASDAQ:QDEL) SVP Werner Kroll sold 16,358 shares of the company’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $40.44, for a total transaction of $661,517.52. Following the sale, the senior vice president now owns 10,818 shares of the company’s stock, valued at $437,479.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Werner Kroll also recently made the following trade(s):
- On Monday, November 6th, Werner Kroll sold 7,565 shares of Quidel stock. The shares were sold at an average price of $39.50, for a total transaction of $298,817.50.
Shares of Quidel Corporation (QDEL) traded down $0.33 during trading on Tuesday, reaching $40.01. 310,099 shares of the company’s stock were exchanged, compared to its average volume of 298,743. The company has a current ratio of 6.28, a quick ratio of 5.68 and a debt-to-equity ratio of 0.70. Quidel Corporation has a fifty-two week low of $18.25 and a fifty-two week high of $45.55.
A number of equities research analysts recently commented on QDEL shares. Canaccord Genuity reiterated a “buy” rating and set a $48.00 price target (up from $42.00) on shares of Quidel in a report on Tuesday, September 19th. Barclays reiterated a “buy” rating and set a $45.00 price target (up from $39.00) on shares of Quidel in a report on Tuesday, September 19th. Raymond James Financial reiterated a “buy” rating and set a $47.00 price target (up from $41.00) on shares of Quidel in a report on Tuesday, September 19th. Piper Jaffray Companies reissued a “buy” rating and set a $50.00 price objective on shares of Quidel in a research report on Friday, November 3rd. Finally, Zacks Investment Research raised shares of Quidel from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Friday, October 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $48.80.
Large investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC grew its position in shares of Quidel by 42.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,678 shares of the company’s stock worth $100,000 after buying an additional 1,091 shares during the period. Great West Life Assurance Co. Can grew its position in shares of Quidel by 162.7% in the 3rd quarter. Great West Life Assurance Co. Can now owns 4,642 shares of the company’s stock worth $204,000 after buying an additional 2,875 shares during the period. Jane Street Group LLC purchased a new stake in shares of Quidel in the 3rd quarter worth about $205,000. Legal & General Group Plc boosted its stake in Quidel by 4.6% in the 1st quarter. Legal & General Group Plc now owns 6,931 shares of the company’s stock worth $157,000 after purchasing an additional 306 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in Quidel in the 2nd quarter worth about $209,000. 92.67% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Insider Selling: Quidel Corporation (QDEL) SVP Sells 16,358 Shares of Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/12/insider-selling-quidel-corporation-qdel-svp-sells-16358-shares-of-stock.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.